Oxidative parameters, oxidative DNA damage, and urotensin-II in schizoaffective disorder patients

References

• Santelmann H, Franklin J, Bußhoff J, et al. Interrater reliability of schizoaffective disorder compared with schizophrenia, bipolar disorder, and unipolar depression – a systematic review and meta-analysis. Schizophr Res. 2016;176:357–363. doi: 10.1016/j.schres.2016.07.012
   PubMed Web of Science ®Google Scholar
• Kasanin JL. The acute schizoaffective psychoses. Am J Psychiatry. 1933;151:144–154.
   Google Scholar
• Heckers S. Is schizoaffective disorder a useful diagnosis? Curr Psychiatry Rep. 2009;11:332–337. doi: 10.1007/s11920-009-0048-3
   PubMed Web of Science ®Google Scholar
• Jager M, Haack S, Becker T, et al. Schizoaffective disorder – an ongoing challenge for psychiatric nosology. Eur Psychiatry. 2011;26:159–165. doi: 10.1016/j.eurpsy.2010.03.010
   PubMed Web of Science ®Google Scholar
• Studentkowski G, Scheele D, Calabrese P, et al. Cognitive impairment in patients with a schizoaffective disorder: a comparison with bipolar patients in euthymia. Eur J Med Res. 2010;15:70–78.
   Web of Science ®Google Scholar
• Torniainen M, Suvisaari J, Partonen T, et al. Cognitive impairments in schizophrenia and schizoaffective disorder: relationship with clinical characteristics. J Nerv Ment Dis. 2012;200:316–322. doi: 10.1097/NMD.0b013e31824cb359
   Web of Science ®Google Scholar
• DeRosse P, Burdick KE, Lencz T, et al. Empirical support for DSM-IV schizoaffective disorder: clinical and cognitive validators from a large patient sample. PLoS One. 2013;30:8.
   Google Scholar
• Amann BL, Canales-Rodriguez EJ, Madre M, et al. Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2016;133:23–33. doi: 10.1111/acps.12440
   Web of Science ®Google Scholar
• Madre M, Radua J, Landin-Romero R, et al. Trait or state? A longitudinal neuropsychological evaluation and fMRI study in schizoaffective disorder. Schizophr Res. 2014;159:458–464. doi: 10.1016/j.schres.2014.08.017
   Web of Science ®Google Scholar
• Gergerlioglu HS, Savas HA, Bulbul F, et al. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:697–702. doi: 10.1016/j.pnpbp.2006.12.020
   PubMed Web of Science ®Google Scholar
• Brown NC, Andreazza AC, Young LT. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 2014;218:61–68. doi: 10.1016/j.psychres.2014.04.005
   PubMed Web of Science ®Google Scholar
• Koga M, Serritella AV, Sawa A, et al. Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophr Res. 2016;176:52–71. doi: 10.1016/j.schres.2015.06.022
   PubMed Web of Science ®Google Scholar
• Yeum KJ, Russell RM, Krinsky NI, et al. Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys. 2004;430:97–103. doi: 10.1016/j.abb.2004.03.006
   PubMed Web of Science ®Google Scholar
• Selek S, Herken H, Bulut M, et al. Oxidative imbalance in obsessive compulsive disorder patients: a total evaluation of oxidant–antioxidant status. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:487–491. doi: 10.1016/j.pnpbp.2007.10.002
   PubMed Web of Science ®Google Scholar
• Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37:112–119. doi: 10.1016/j.clinbiochem.2003.10.014
   PubMed Web of Science ®Google Scholar
• Yumru M, Savas HA, Kalenderoglu A, et al. Oxidative imbalance in bipolar disorder subtypes: a comparative study. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1070–1074. doi: 10.1016/j.pnpbp.2009.06.005
   PubMed Web of Science ®Google Scholar
• Albayrak Y, Unsal C, Beyazyuz M, et al. Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:144–149. doi: 10.1016/j.pnpbp.2013.04.020
   PubMed Web of Science ®Google Scholar
• Bulbul F, Alpak G, Unal A, et al. New molecule in the etiology of schizophrenia: urotensin II. Psychiatry Clin Neurosci. 2014;68:133–136. doi: 10.1111/pcn.12099
   Web of Science ®Google Scholar
• Naoya N, Arnold SE. Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry. 2004;12:167–175. doi: 10.1097/00019442-200403000-00008
   Web of Science ®Google Scholar
• Kim HJ, Soh Y, Jang JH, et al. Differential cell death induced by salsolinol with and without copper: possible role of reactive oxygen species. Mol Pharmacol. 2001;60:440–449.
   PubMed Web of Science ®Google Scholar
• Tuzgen S, Hamnimoglu H, Tanriverdi T, et al. Relationship between DNA damage and total antioxidant capacity in patients with glioblastoma multiforme. Clin Oncol. 2007;19:177–181. doi: 10.1016/j.clon.2006.11.012
   PubMed Web of Science ®Google Scholar
• Barrette PO, Schwertani AG. A closer look at the role of urotensin II in the metabolic syndrome. Front Endocrinol. 2012;3:165. doi: 10.3389/fendo.2012.00165
   Google Scholar
• Ross B, McKendy K, Giaid A. Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol. 2010;298:1156–1172. doi: 10.1152/ajpregu.00706.2009
   PubMed Web of Science ®Google Scholar
• Bern HA, Pearson D, Larson BA, et al. Neurohormones from fish tails: the caudal neurosecretory system. I. “Urophysiology” and the caudal neurosecretory system of fishes. Recent Prog Horm Res. 1985;41:533–552.
   PubMedGoogle Scholar
• Castel H, Desrues L, Joubert JE, et al. The G protein-coupled receptor UT of the neuropeptide urotensin II displays structural and functional chemokine features. Front Endocrinol. 2017;8:76. doi: 10.3389/fendo.2017.00076
   Web of Science ®Google Scholar
• Bulbul F, Virit O, Alpak G, et al. Are oxidative stress markers useful to distinguish schizoaffective disorder from schizophrenia and bipolar disorder? Acta Neuropsychiatr. 2014;26:120–124. doi: 10.1017/neu.2013.44
   Web of Science ®Google Scholar
• Kostakoğlu AE, Batur S, Tiryaki A, et al. Pozitif ve negatif sendrom ölceğinin (PANSS) Türkçe uyarlamasının geçerlilik ve güvenilirliği. Turk Psikoloji Dergisi. 1999;14(44):23–32.
   Web of Science ®Google Scholar
• Akdemir A, Türkçapar MH, Orsel SD, et al. Reliability and validity of the Turkish version of the Hamilton depression rating scale. Compr Psychiatry. 2001;2(2):161–165. doi: 10.1053/comp.2001.19756
   Web of Science ®Google Scholar
• Karadağ F, Oral ET, Aran Yalçın F, et al. Young Mani Derecelendirme Ölçeği’nin Türkiye’de geçerlik ve güvenirliği. Türk Psikiyatri Dergisi. 2002;13(2):107–114.
   PubMedGoogle Scholar
• Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38:1103–1111. doi: 10.1016/j.clinbiochem.2005.08.008
   PubMed Web of Science ®Google Scholar
• Ames RS, Sarau HM, Chambers JK, et al. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401:282–286. doi: 10.1038/45809
   PubMed Web of Science ®Google Scholar
• Hillier C, Berry C, Petrie MC, et al. Effects of urotensin II in human arteries and veins of varying caliber. Circulation. 2001;103:1378–1381. doi: 10.1161/01.CIR.103.10.1378
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F. Urotensin II: a cardiovascular and renal update. Curr Opin in Nephrol Hypertens. 2008;17:199–204. doi: 10.1097/MNH.0b013e3282f49566
   PubMed Web of Science ®Google Scholar
• Babińska M, Holecki M, Prochaczek F, et al. Is plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome? Arch Med Sci. 2012;8:449–454. doi: 10.5114/aoms.2012.29521
   Web of Science ®Google Scholar
• Gartlon J, Parker F, Harrison DC, et al. Central effects of urotensin-II following ICV administration in rats. Psychopharmacology. 2001;155:426–433. doi: 10.1007/s002130100715
   PubMed Web of Science ®Google Scholar
• Mueller LE, Kausch MA, Markovic T, et al. Intra-ventral tegmental area microinjections of urotensin II modulate the effects of cocaine. Behav Brain Res. 2015;278:271–279. doi: 10.1016/j.bbr.2014.09.036
   Web of Science ®Google Scholar
• Morimoto R, Satoh F, Murakami O, et al. Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues. Peptides. 2008;29:873–880. doi: 10.1016/j.peptides.2007.06.025
   Web of Science ®Google Scholar
• Takahashi K, Totsune K, Murakami O, et al. Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. Peptides. 2003;24:301–306. doi: 10.1016/S0196-9781(03)00039-1
   Web of Science ®Google Scholar
• Desrues L, Lefebvre T, Lecointre C, et al. Downregulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity. PLoS One. 2012;7(5):e36319. doi: 10.1371/journal.pone.0036319
   Web of Science ®Google Scholar
• Takahashi K, Totsune K, Murakami O, et al. Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides. 2001;22:1175–1179. doi: 10.1016/S0196-9781(01)00441-7
   PubMed Web of Science ®Google Scholar
• Lecointre C, Desrues L, Joubert JE, et al. Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma. Oncogene. 2015;34:5080–5094. doi: 10.1038/onc.2014.433
   Web of Science ®Google Scholar
• Balakan O, Kalender ME, Suner A, et al. The relationship between urotensin II and its receptor and the clinicopath-ological parameters of breast cancer. Med Sci Monit. 2014;20:1419–1425. doi: 10.12659/MSM.890459
   Web of Science ®Google Scholar
• Stuart MJ, Baunea BT. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev. 2014;42:93–115. doi: 10.1016/j.neubiorev.2014.02.001
   PubMed Web of Science ®Google Scholar
• Madre M, Canales-Rodriguez EJ, Ortiz-Gil J, et al. Neuropsychological and neuroimaging underpinnings of schizoaffective disorder: a systematic review. Acta Psychiatr Scand. 2016;134:16–30. doi: 10.1111/acps.12564
   Web of Science ®Google Scholar
• Cheniaux E, Landeira-Fernandez J, Lessa Telles L, et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord. 2008;106:209–217. doi: 10.1016/j.jad.2007.07.009
   PubMed Web of Science ®Google Scholar
• Al-chalabi BM, Thanoon AJ, Ammed FA. Potential effect of olanzapine on total antioxi-dant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology. 2009;59:8–11. doi: 10.1159/000202823
   Web of Science ®Google Scholar
• Pazvantoglu O, Selek S, Okay IT, et al. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin Neurosci. 2009;63:693–700. doi: 10.1111/j.1440-1819.2009.02015.x
   PubMed Web of Science ®Google Scholar
• Arvindakshan M, Ghate M, Ranjekar PK, et al. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res. 2003;62:195–204. doi: 10.1016/S0920-9964(02)00284-0
   PubMed Web of Science ®Google Scholar
• Fenton WS, Dickerson F, Boronow J, et al. Placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001;158:2071–2074. doi: 10.1176/appi.ajp.158.12.2071
   PubMed Web of Science ®Google Scholar
• Sivrioglu EY, Kirli S, Sipahioglu D, et al. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1493–1499. doi: 10.1016/j.pnpbp.2007.07.004
   PubMed Web of Science ®Google Scholar
• Kunz M, Gama CS, Andreazza AC, et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1677–1681. doi: 10.1016/j.pnpbp.2008.07.001
   PubMed Web of Science ®Google Scholar
• Soeiro-de-Souza MG, Andreazza AC, Carvalho AF, et al. Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol. 2013;16:1505–1512. doi: 10.1017/S1461145713000047
   PubMed Web of Science ®Google Scholar
• Koh PO, Undie AS, Kabbani N, et al. Up-regulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of schizophrenic and bipolar patients. Proc Natl Acad Sci. 2003;100(1):313–317. doi: 10.1073/pnas.232693499
   Web of Science ®Google Scholar
• Vawter MP, Crook JM, Hyde TM, et al. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res. 2002;58(1):11–20. doi: 10.1016/S0920-9964(01)00377-2
   Web of Science ®Google Scholar
• Andreazza AC, Frey BN, Erdtmann B, et al. DNA damage in bipolar disorder. Psychiatry Res. 2007;153:27–32. doi: 10.1016/j.psychres.2006.03.025
   PubMed Web of Science ®Google Scholar
• Jorgensen A, Broedbaek K, Fink-Jensen A, et al. Increased systemic oxidatively generated DNA and RNA damage in schizophrenia. Psychiatry Res. 1933;209:417–423. doi: 10.1016/j.psychres.2013.01.033
   Web of Science ®Google Scholar
• Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013;74:400–409. doi: 10.1016/j.biopsych.2013.03.018
   PubMed Web of Science ®Google Scholar